The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Ingenol Mebutate Gel for Actinic Keratosis
Open accessAbstract
BACKGROUND: Actinic keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical and subclinical actinic keratoses. Topical field therapy currently requires weeks or months of treatment. We investigated the efficacy and safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk and extremities). METHODS: In four multicenter, randomized, double-blind studies, we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extremities to receive ingenol mebutate or placebo (vehicle), self-applied to a 25-cm(2) contiguous field once daily for 3 consecutive days for lesions on the face or scalp or for 2 consecutive days for the trunk or extremities. Complete clearance (primary outcome) was assessed at 57 days, and local reactions were quantitatively measured. RESULTS: In a pooled analysis of the two trials involving the face and scalp, the rate of complete clearance was higher with ingenol mebutate than with placebo (42.2% vs. 3.7%, P<0.001). Local reactions peaked at day 4, with a mean maximum composite score of 9.1 on the local-skin-response scale (which ranges from 0 to 4 for six types of reaction, yielding a composite score of 0 to 24, with higher numbers indicating more severe reactions), rapidly decreased by day 8, and continued to decrease, approaching baseline scores by day 29. In a pooled analysis of the two trials involving the trunk and extremities, the rate of complete clearance was also higher with ingenol mebutate than with placebo (34.1% vs. 4.7%, P<0.001). Local skin reactions peaked between days 3 and 8 and declined rapidly, approaching baseline by day 29, with a mean maximum score of 6.8. Adverse events were generally mild to moderate in intensity and resolved without sequelae. CONCLUSIONS: Ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses. (Funded by LEO Pharma; ClinicalTrials.gov numbers, NCT00742391, NCT00916006, NCT00915551, and NCT00942604.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
Self-citationAntitumor Activity of 3-Ingenyl Angelate
Ogbourne, S. M., Suhrbier, A., Jones, B., Cozzi, S.-J., Boyle, G. M., Morris, M., McAlpine, D., Johns, J., Scott, T. M., Sutherland, K. P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2837 · Cited by 255
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
Wolf, J. E., Taylor, J. R., Tschen, E., & Kang, S. (2001) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2001.01324.x · Cited by 238
Rivers, J. K., Arlette, J., Shear, N., Guenther, L., Carey, W., & Poulin, Y. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04561.x · Cited by 215
Development of a treatment algorithm for actinic keratoses: a European Consensus.
Stockfleth, E., Ferrándiz, C., Grob, J., Leigh, I. M., Pehamberger, H., & Kerl, H. (2009) · PubMed · doi:10.1684/ejd.2008.0514 · Cited by 188
Challacombe, J. M., Suhrbier, A., Parsons, P. G., Jones, B., Hampson, P., Kavanagh, D., Rainger, G. E., Morris, M., Lord, J. M., Le, T. T. T., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8123 · Cited by 177
Swanson, N. A., Abramovits, W., Berman, B., Kulp, J., Rigel, D. S., & Levy, S. F. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.07.004 · Cited by 160
Self-citationHanke, C. W., Beer, K. R., Stockfleth, E., Wu, J. K., Rosen, T., & Levy, S. F. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.020 · Cited by 155
Dynamic balanced randomization for clinical trials
Signorini, D. F., Leung, O. K., Simes, R. J., Beller, E., Gebski, V., & Callaghan, T. (1993) · Statistics in Medicine · doi:10.1002/sim.4780122410 · Cited by 141
Guidelines of care for actinic keratoses
Drake, L. A., Ceilley, R. I., Cornelison, R. L., DOBES, W. L., Dorner, W., Goltz, R. W., Graham, G. F., Lewis, C. W., Salasche, S. J., Turner, M. L. C., et al. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90191-4 · Cited by 113
Cited by
Cragg, G. M., & Pezzuto, J. M. (2016) · Medical Principles and Practice · doi:10.1159/000443404 · Cited by 798
Medicinal plants in Brazil: Pharmacological studies, drug discovery, challenges and perspectives
Dutra, R. C., Campos, M. M., Santos, A. R. S., & Calixto, J. B. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.021 · Cited by 439
Cutaneous Squamous Cell Carcinoma
Waldman, A., & Schmults, C. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.08.001 · Cited by 424
Skin cancer prevention: a review of current topical options complementary to sunscreens
Rosenthal, A., Stoddard, M., Chipps, L., & Herrmann, J. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15522 · Cited by 28
Ethnopharmacology and Drug Discovery
Heinrich, M. (2013) · Reference Module in Chemistry, Molecular Sciences and Chemical Engineering · doi:10.1016/b978-0-12-409547-2.02773-6 · Cited by 20
Metadata
- Authors
- Lebwohl, M., Swanson, N., Anderson, L. L., Melgaard, A., Xu, Z., & Berman, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-15
- Volume
- 366
- Issue
- 11
- Pages
- 1010-1019
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2132174517
- Cited by
- 471
- References
- 12
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ingenol Mebutate Gel for Actinic Keratosis. https://app.cochat.ai/papers/10.1056/nejmoa1111170
- The paper
- Lebwohl, M., Swanson, N., Anderson, L. L., Melgaard, A., Xu, Z., & Berman, B. (2012). Ingenol Mebutate Gel for Actinic Keratosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1111170
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.